Gongwinbiopharm PTS

We at Gongwin Biopharm Co., Ltd are researching and developing an innovative Minimally Invasive Targeted Tumor Ablation technique for treating focal malignancies. Our proprietary core technology is intra-tumoral injection of PTS (Para Toluene Sulfonamide) by combining the active therapeutic agent and following minimally invasive intervention techniques, which is unique and distinct from traditional anti-tumor therapies that are being opted by medical professionals. Core benefits for patients: Targeted selectivity Onset within 24hours of injection & almost no damage to adjacent tissue. Broader Efficacy Application in head & neck, breast, lung, liver & other cancer types. Safety No severe systemic toxicities.

Malignant pleural effusion; adenoid cystic carcinoma; primary liver cancer; central lung cancer tracheal obstruction; and atopic dermatitis

Gongwinbiopharm pts operates in the Biotechnology research industry.

Gongwinbiopharm pts has 51 - 200 employees.